Organogenesis Hldgs Inc Stock Price, News & Analysis

Organogenesis Holdings (Nasdaq: ORGO) will announce its fourth quarter and fiscal year 2021 financial results on March 1, 2022, after market close. Management will discuss these results in a conference call at 5:00 p.m. ET, which is open to participants via a dedicated phone line or a live webcast on the investor relations section of their website. A replay will be available for two weeks post-call. Organogenesis specializes in regenerative medicine, focusing on solutions for advanced wound care and surgical and sports medicine.

Organogenesis Holdings Inc. (Nasdaq: ORGO) announced the appointment of Prathyusha Duraibabu to its Board of Directors as of November 19, 2021. Ms. Duraibabu brings over 24 years of expertise in technology and healthcare, having held senior roles at global biotechnology firms. Currently the CFO of Sangamo Therapeutics, she has also served as Corporate Controller at Pacific Biosciences. The addition is expected to enhance the Board's strategic insight and oversight, particularly within the Audit Committee.

Organogenesis Holdings Inc. (Nasdaq: ORGO) reported Q3 2021 net revenue of $113.8 million, a 13% increase year-over-year. Advanced Wound Care products drove revenue growth, contributing $107.3 million, up 19% compared to Q3 2020. However, Surgical & Sports Medicine revenue fell 41% to $6.4 million. Net income decreased to $12.6 million from $20.8 million in Q3 2020. Operating expenses rose 30% to $71.3 million, impacting profitability. The company forecasts 2021 net revenue between $458 million and $470 million, a 35% to 39% increase year-over-year.

Organogenesis Holdings (Nasdaq: ORGO) will participate in the Credit Suisse 30th Annual Healthcare Conference from November 8-11, 2021. A fireside chat featuring company management is scheduled for November 11 at 9:40 a.m. ET. The event will be held virtually, and a live audio webcast will be accessible via the ‘Upcoming Events’ section on Organogenesis’s Investor Relations page. An archived version of the webcast will be available for 30 days post-conference.

Organogenesis specializes in regenerative medicine, offering bioactive products for advanced wound care and surgical markets.

Organogenesis Holdings Inc. (Nasdaq: ORGO) will showcase advanced wound care research at the 2021 Symposium on Advanced Wound Care Fall Conference in Las Vegas from October 29-31. Key presentations include a lunch symposium discussing in vivo data on PuraPly technology and a session on dermal substitutes post-Mohs surgery. The company also highlights its Adjustable Curette, aimed at enhancing wound debridement. Organogenesis, a leader in regenerative medicine, focuses on innovative solutions for advanced wound care and surgical applications.

Organogenesis Holdings Inc. (Nasdaq: ORGO) announced that it will release its third-quarter financial results on November 9, 2021, after the market closes. The company will hold a conference call at 5:00 p.m. ET the same day to discuss these results and provide updates on corporate developments. Participation can be done via a dedicated phone line and a live webcast will be available on their investor relations website. Organogenesis specializes in regenerative medicine, focusing on advanced wound care and surgical biologics.

Organogenesis Holdings has announced their participation in two significant investor conferences. The management will engage in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14th at 1:15 p.m. ET. Additionally, they will present at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on September 20th at 3:45 p.m. ET. Live audio webcasts will be available on their website, with replays accessible for 30 days post-conference.

Organogenesis Holdings Inc. (Nasdaq: ORGO) has partnered with Net Health to become the first to utilize Net Health's CTP Connections Module, enabling the electronic submission of insurance benefits verification forms. This initiative aims to enhance efficiency for hospital and outpatient wound care providers in verifying benefits for Organogenesis's cell and tissue-based products. The service is provided at no extra cost to Net Health Wound Care users, minimizing administrative errors and speeding up responses from payors, ultimately improving patient access to critical products.

Organogenesis Holdings Inc. (Nasdaq: ORGO) reported robust financial results for Q2 2021, with net revenue reaching $123.2 million, a 79% increase year-over-year. Key drivers included Advanced Wound Care products at $111.4 million (up 87%) and Surgical & Sports Medicine at $11.8 million (up 27%). The company achieved a net income of $20.7 million, reversing a loss of $5.2 million in Q2 2020. Adjusted EBITDA increased to $25.1 million, or 20.4% of net revenue, compared to $0.3 million in the prior year.